Clinical biomarker potential of spectrin breakdown degradation products: a systematic review
SBDPs, such as SBDP120, 145, and 150, show promise as biomarkers of neuronal injury, although evidence is limited in some clinical conditions, however, their clinical applicability remains context-dependent and is currently limited by methodological heterogeneity. Standardized assays, larger cohorts, and longitudinal studies are needed to strengthen the existing promising evidence.
Authors
- Niharika Ikkurthy (ORCID: https://orcid.org/0000-0002-5315-0630)
- Gilda Silven
- Sharon Philip Jain
- Shervinchris Philip Jain
Institutions
- Jubilee Mission Medical College and Research Institute (IN)
- David Tvildiani Medical University (GE)
- Cedars-Sinai Smidt Heart Institute (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/03007995.2026.2633459
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 0.00